Ocular

CAM360

AmnioGraftTM

Developed to Optimize Comfort.

CAM360 AmnioGraft™ (CAM360 AG) is the first and only hydrated, cryopreserved amniotic membrane developed to optimize comfort that exerts anti-inflammatory, anti-scarring, anti-angiogenic properties for ocular use.1

Simple & Effective

We’re proud to introduce a CAM solution that will expand patient access while also providing physicians with a simple storage solution.

01

CAM360 AG is a comfortable, ringless, Cryopreserved Amniotic Membrane (CAM) option, ideal for superficial conditions.

02

Our SteriTek preservation process yields a shelf-stable product, protecting the bioactive components of the tissue without heat dehydration.2

03

Our proprietary processing method preserves the tissue’s unique, adhesive property allowing CAM360 AG to stick & stay under a Collagen Shield or Bandage Contact Lens (BCLs).4

Key Orchestrator

Preserving HC-HA/PTX3

HC-HA/PTX3 is a key matrix found within fresh and cryopreserved tissues that may be responsible for Amniotic Membrane’s (AM) therapeutic benefits.3

BioTissue’s proprietary CryoTek® and SteriTek® preservation methods are the only proven processing methods that retain the HC-HA/PTX3 found in fresh tissue.4 Our processing methods were specifically designed to optimize preservation while also providing efficiencies in handling, storage, and product application.

Sign up for our Physician Portal to access product info, clinical resources, and updates to support your practice!

Applications
  • Applications
  • Packaging & Storage
  • User Guide
  • Resources
  • Customer Support
  • Applications
  • Packaging & Storage
  • User Guide
  • Resources
  • Customer Support

Applications:

  • Dry Eye Disease
  • Superficial Punctate Keratitis (SPK)
  • Ocular Surface Optimization
  • Glaucoma-Medication Induced Dry Eye
  • Neurotrophic Keratitis Stage 1

CAM has been shown to:2,5-8

• Reduce signs and symptoms of Dry Eye Disease (DED)
• Support epithelial adhesion and differentiation
• Promote corneal nerve regeneration

 

Location & Temperature

-20°C → 25°C ( -4°F  →  77°F)

Shelf Life

Use within the expiration date printed on product packaging (1 years from date of manufacture).

See CAM360 AG Product Insert

Physician Resources:

Explore the resources below to support your practice and improve patient care.

 

Access the Physician Portal

For additional resources like clinical studies, product information, etc.

BioTissue Ocular Customer Support:

Call us Monday – Friday: 9:00 a.m. to 7:00 p.m. Eastern Standard Time.

Email: [email protected]
Call: (888) 296-8858
Fax: (305) 412-4429

For more information, visit our Ordering page.

 

Discover how CAM360 can Help Improve Patient Comfort

Fill out the details below to download the CAM360 AG Brochure:
By clicking the button below, I agree to receive marketing communications from BioTissue. I am aware that I can unsubscribe at any time.
This field is for validation purposes and should be left unchanged.
Testimonials

“Dry eye took over my life for the last few years without a solution I was satisfied with. With a simple treatment like CAM360 AG, I can return to my daily routine.”

– CAM360 AG Patient

Report any feedback or unexpected reactions by emailing [email protected].

References
FDA RFD
Data on File
Tighe, S., Mead, O. G., Lee, A., & Tseng, S. C. G. (2020). Basic science review of birth tissue uses in ophthalmology. Taiwan Journal of Ophthalmology, 10(1), 3–12.
Cooke, M., . (2014). Comparison of cryopreserved amniotic membrane and umbilical cord tissue with dehydrated amniotic membrane/chorion tissue. Journal of Wound Care, 23(10), 465-476.
John, T., et al. (2017). Corneal nerve regeneration after self-retained cryopreserved amniotic membrane in dry eye disease. Journal of Ophthalmology, 2017.
McDonald, M. B., et al. (2018). Treatment outcomes in the dry eye amniotic membrane (DREAM) study. Clinical Ophthalmology (Auckland, NZ), 12, 677.
Cheng, A. M., et al. (2016). Accelerated restoration of ocular surface health in dry eye disease by self-retained cryopreserved amniotic membrane. The Ocular Surface, 14(1), 56-63.
Vendal, Z. (2022). Management of glaucoma medication induced dry eye disease with self-retained cryopreserved amniotic membrane. Journal of Dry Eye Disease, 5(1), e28-e34.